AME Stockholders Approve Acquisition By Lilly
11 Febrero 2004 - 1:24PM
PR Newswire (US)
AME Stockholders Approve Acquisition By Lilly SAN DIEGO, Feb. 11
/PRNewswire-FirstCall/ -- Applied Molecular Evolution, Inc. (AME)
announced that, at a special meeting held today, its stockholders
voted to approve the proposed merger transaction with Eli Lilly and
Company , under which AME will become a wholly owned subsidiary of
Lilly. The merger was approved with a significant majority of
outstanding shares voted. Based on preliminary results, out of the
14,114,815 million shares voted, approximately 99.7 percent were
voted in favor of the merger. The merger is expected to be
consummated at the close of business on February 12, 2004 or
shortly thereafter. About AME Applied Molecular Evolution, Inc. is
a leader in applying directed molecular evolution to improve
healthcare by optimizing and developing human biotherapeutics.
Directed molecular evolution is a process for optimizing genes and
proteins for specific commercial purposes. Since its inception,
AME's principal focus has been on applying its proprietary
AMEsystem(TM) technology platform to human biotherapeutics, the
largest market for directed molecular evolution. Biotherapeutics,
or biopharmaceuticals, are protein pharmaceuticals such as
antibodies, cytokines, hormones and enzymes. AME uses its
proprietary technology to develop improved versions of currently
marketed, FDA-approved biopharmaceuticals as well as novel human
biotherapeutics. About Lilly Eli Lilly and Company, a leading
innovation-driven corporation, is developing a growing portfolio of
first-in-class and best-in-class pharmaceutical products by
applying the latest research from its own worldwide laboratories
and from collaborations with eminent scientific organizations.
Headquartered in Indianapolis, Indiana, Lilly provides answers --
through medicines and information -- for some of the world's most
urgent medical needs. Additional information about Lilly is
available at http://www.lilly.com/ . Forward Looking Statements
This press release containsforward-looking statements that are
subject to risks and uncertainties that could cause actual results
to differ materially from those set forth in the forward-looking
statements. The potential risks and uncertainties include, among
other risks, whether Lilly will successfully complete the
acquisition, the reaction of the customers of Lilly and AME to the
acquisition, Lilly's ability to successfully integrate AME's
operations and employees and general economic conditions. These
forward-looking statements represent AME's judgment as of the date
of this press release. AME disclaims any intent or obligation to
update these forward-looking statements. More information about
potential factors that could affect AME's business and financial
results is included in AME's Annual Report on Form 10-K for the
fiscal year ended December 31, 2002 and other Securities and
Exchange Commission filings. For more information, please contact
Chris Erdman of AME, +1-858-638-8635. DATASOURCE: Applied Molecular
Evolution, Inc. CONTACT: Chris Erdman of AME, +1-858-638-8635 Web
site: http://www.lilly.com/ Web site: http://www.ame.biz/
Copyright
Applied Molecular Evolution (NASDAQ:AMEV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Applied Molecular Evolution (NASDAQ:AMEV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Applied Molecular Evolution, (MM) (NASDAQ): 0 recent articles
Más de Applied Molecular Evolution, (MM) Artículos de Noticias